Cecilia Brown

Cecilia Brown is an assistant editor for Mashup Media, the parent company of GU Oncology Now. Cecilia is a medical writer and editor with over four years of experience in publishing and journalism, as well as several years of research experience. She can be reached at CBrown@mashupmd.com.

Articles by Cecilia Brown

Cecilia BrownAdvanced Urothelial Carcinoma | November 10, 2022
Shilpa Gupta, MD, discusses the impact of immune checkpoint inhibitors on care of patients with advanced bladder cancer.
View More
Cecilia BrownAdvanced Urothelial Carcinoma | November 14, 2022
An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases.
Cecilia BrownAdvanced Urothelial Carcinoma | November 10, 2022
Enfortumab vedotin led to longer OS than chemotherapy in previously treated urothelial carcinoma.
Cecilia BrownAdvanced Urothelial Carcinoma | November 10, 2022
Most patients with locally advanced or metastatic urothelial carcinoma did not receive first-line systemic therapy.
Cecilia BrownAdvanced Urothelial Carcinoma | October 27, 2022
Enfortumab vedotin ranks first in efficacy among 6 treatments for metastatic urothelial cancer.
Cecilia BrownAdvanced Urothelial Carcinoma | October 14, 2022
Shilpa Gupta, MD, discusses treatments for cisplatin-ineligible patients with advanced bladder cancer.
Cecilia BrownAdvanced Urothelial Carcinoma | October 14, 2022
Women with advanced urothelial carcinoma have a significantly greater risk of progression after chemotherapy than men.
Cecilia BrownAdvanced Urothelial Carcinoma | October 14, 2022
Lymphovascular invasion in upper tract urothelial carcinoma puts patients at higher risk for recurrence and mortality.
Cecilia BrownAdvanced Urothelial Carcinoma | September 26, 2022
The pretreatment albumin-globulin ratio can independently predict survival outcomes in patients with urothelial carcinoma.
Cecilia BrownAdvanced Urothelial Carcinoma | September 26, 2022
Researchers identified the top reason why some patients with urothelial carcinoma don't pursue treatment.
Cecilia BrownAdvanced Urothelial Carcinoma | October 14, 2022
Shilpa Gupta, MD, discusses recent developments in targeted molecular therapeutics for advanced bladder cancer.
Cecilia BrownAdvanced Urothelial Carcinoma | September 26, 2022
Enfortumab vedotin plus pembrolizumab led to an ORR of 73.3% in cisplatin-ineligible patients with urothelial cancer.
Cecilia BrownUrothelial Carcinoma | September 21, 2022
Dr. Mary Beth Westerman, speaks on notable advances that she has see in bladder cancer throughout her career.
Cecilia BrownUrothelial Carcinoma | September 21, 2022
Dr. Westerman speaks on what clinicians can do to improve pre-operative counseling for female patients with bladder cancer.
Cecilia BrownUrothelial Carcinoma | September 21, 2022
Dr. Mary Beth Westerman provides insight on some of the main challenges in treating women with bladder cancer.
Cecilia BrownRenal Cell Carcinoma | September 21, 2022
Treatment with an ICI plus a VEGF receptor inhibitor showed increased likelihood of obtaining an objective imaging response.
Cecilia BrownProstate Cancer | August 16, 2022
Failure-free survival rates between focal cryoablation and stereotactic body radiotherapy for prostate cancer no different.
Cecilia BrownMuscle Invasive Urothelial Carcinoma | August 15, 2022
A trial utilized atezolizumab, a monoclonal antibody directed at the PD-L1 protein, in patients with MIBC.
Cecilia BrownmCSPC | October 12, 2023
The FDA has approved the use of darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer.
Cecilia BrownNon-Muscle Invasive Urothelial Carcinoma | August 8, 2022
The induction lymphocyte-to-monocyte ratio was associated with “better accuracy” and than the preoperative ratio.